Exhaled breath analysis with the use of an electronic nose to predict response to immune checkpoint inhibitors in patients with metastatic melanoma: melaNose trial
Exhaled breath analysis using eNose can identify patients with metastatic melanoma who will not benefit from first-line treatment with ICIs and guide treatment strategies. When validated in an external cohort, eNose could be a useful tool to select these patients for alternative treatment strategies in clinical practice.
Authors
- Astrid A.M. van der Veldt (ORCID: https://orcid.org/0000-0003-0446-1907)
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- Brigit van Dijk
- Ivonne J. H. Schoenaker (ORCID: https://orcid.org/0000-0002-8628-8134)
Institutions
- Erasmus MC (NL)
- Isala (NL)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1564463
- Primary Topic
- Advanced Chemical Sensor Technologies
- Type
- article
- Field-Weighted Citation Impact
- 0.00